- Home
- MIRM vs ASO Comparison
MIRM vs ASO Comparison
Compare MIRM & ASO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- ASO
- Stock Information
- Founded
- MIRM 2018
- ASO 1938
- Country
- MIRM United States
- ASO United States
- Employees
- MIRM N/A
- ASO N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- ASO Recreational Games/Products/Toys
- Sector
- MIRM Health Care
- ASO Consumer Discretionary
- Exchange
- MIRM Nasdaq
- ASO Nasdaq
- Market Cap
- MIRM 3.3B
- ASO 3.0B
- IPO Year
- MIRM 2019
- ASO 2020
- Fundamental
- Price
- MIRM $67.93
- ASO $54.02
- Analyst Decision
- MIRM Strong Buy
- ASO Buy
- Analyst Count
- MIRM 9
- ASO 18
- Target Price
- MIRM $73.89
- ASO $58.06
- AVG Volume (30 Days)
- MIRM 661.2K
- ASO 1.3M
- Earning Date
- MIRM 08-06-2025
- ASO 09-09-2025
- Dividend Yield
- MIRM N/A
- ASO 0.95%
- EPS Growth
- MIRM N/A
- ASO N/A
- EPS
- MIRM N/A
- ASO 5.46
- Revenue
- MIRM $429,161,000.00
- ASO $5,920,639,000.00
- Revenue This Year
- MIRM $36.76
- ASO $3.73
- Revenue Next Year
- MIRM $17.48
- ASO $6.47
- P/E Ratio
- MIRM N/A
- ASO $9.90
- Revenue Growth
- MIRM 62.33
- ASO N/A
- 52 Week Low
- MIRM $36.86
- ASO $33.34
- 52 Week High
- MIRM $69.00
- ASO $64.62
- Technical
- Relative Strength Index (RSI)
- MIRM 82.95
- ASO 57.71
- Support Level
- MIRM $50.25
- ASO $48.96
- Resistance Level
- MIRM $67.45
- ASO $55.82
- Average True Range (ATR)
- MIRM 2.89
- ASO 1.89
- MACD
- MIRM 1.38
- ASO 0.02
- Stochastic Oscillator
- MIRM 94.29
- ASO 70.98
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About ASO Academy Sports and Outdoors Inc.
Academy Sports and Outdoors Inc is engaged in the full-line sporting goods and outdoor recreation retailer in the United States. The company's product categories are outdoors, apparel, sports & recreation, and footwear.